Clinical Trial Update: A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing A-FOLFOXIRI vs A-FOLFIRI/FOLFOX as first-line treatment for unresectable metastatic right-sided colon cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Right-sided Colon Cancer
• Unresectable Metastatic Colon Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Infusional fluorouracil (fluorouracil)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Yonsei University | Conditions: Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV | Phase 2 | Status: UNKNOWN